Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients
Background: Iron overload is a predictable and lifethreatening complication in patients with thalassemia. Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major. The development of a safe and effective chelator has been the goal for m...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Krishna Vishwa Vidyapeeth (Deemed to be University), Karad
2015-01-01
|
| Series: | Journal of Krishna Institute of Medical Sciences University |
| Subjects: | |
| Online Access: | http://jkimsu.com/jkimsu-vol4no1/JKIMSU,%20Vol.%204,%20No.%201,%20Jan-Mar%202015%20Page%2070-76.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850264479886999552 |
|---|---|
| author | Nargesbeygom Mirbehbahani Azam Jahazi Haniye Mohsenkhah Amlashi Naser Behnampour |
| author_facet | Nargesbeygom Mirbehbahani Azam Jahazi Haniye Mohsenkhah Amlashi Naser Behnampour |
| author_sort | Nargesbeygom Mirbehbahani |
| collection | DOAJ |
| description | Background: Iron overload is a predictable and lifethreatening
complication in patients with thalassemia.
Effective and convenient iron chelation remains one of
the main targets of clinical management of thalassemia
major. The development of a safe and effective chelator
has been the goal for many years. Aims and Objective:
It was aimed to compare the effect of deferiprone,
deferoxamine and combination of deferiprone and
deferoxamine on serum ferritin value in betathalassemia
patients. Material and Methods: This
controlled clinical trial was conducted on 46 major
beta-thalassemic patients. Fifteen patients in
deferiprone group received deferiprone 75mg/kg/day
three times a day orally. Nineteen patients in
deferoxamine group received deferoxamine 30-50
mg/kg/day subcutaneously for 8-12 hours/day and 5
days per week. Twelve patients in combined therapy
group received deferiprone 75 mg/kg/day three times a
day orally with deferoxamine 30–50 mg/kg subcutaneously
every other day. Serum ferritin value was
th th measured at the beginning and at the end of 6 and 12
months of study. Results: The mean of serum ferritin
value in deferiprone group insignificantly increased
from 2731± 1398.5 µg/L at the beginning to 2788.5 ±
th 978.6 µg/L and to 3331.8 ± 1833.9 µg/L at the end of 6
th and 12 months of study, respectively. The mean of
serum ferritin value in deferoxamine group insignificantly
increased from 2883.5 ± 1598.1 µg/L at the
th beginning to 2935.3 ± 1258.2 µg/L at the end of 6
month of study and decreased to 2773.8 ± 1216.1 µg/L
th and 12 month of study. The mean of serum ferritin
level in combined therapy group significantly
decreased from 7498.7 ± 3512.9 µg/L at the beginning
to 4839.9 ± 2698.2 µg/L (P < 0.001) and to 4298.2 ±
th th 2288.7 µg/L (P < 0.001) at the end of 6 and 12 months of study, respectively. Conclusion: Combined therapy
significantly decreases serum ferritin level. Study
suggests deferiprone as a significant addition to
support therapy in patients with betathalassemia major
on regular transfusion regimens. |
| format | Article |
| id | doaj-art-ef45f06563c040b182ccee2c45ec124d |
| institution | OA Journals |
| issn | 2231-4261 2231-4261 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Krishna Vishwa Vidyapeeth (Deemed to be University), Karad |
| record_format | Article |
| series | Journal of Krishna Institute of Medical Sciences University |
| spelling | doaj-art-ef45f06563c040b182ccee2c45ec124d2025-08-20T01:54:41ZengKrishna Vishwa Vidyapeeth (Deemed to be University), KaradJournal of Krishna Institute of Medical Sciences University2231-42612231-42612015-01-01417076Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia PatientsNargesbeygom Mirbehbahani 0Azam Jahazi1Haniye Mohsenkhah Amlashi2Naser Behnampour3Islamic Azad University Gorgan Branch, Gorgan, Golestan-0098, IranIslamic Azad University Gorgan Branch, Gorgan, Golestan-0098, IranIslamic Azad University Gorgan Branch, Gorgan, Golestan-0098, IranIslamic Azad University Gorgan Branch, Gorgan, Golestan-0098, IranBackground: Iron overload is a predictable and lifethreatening complication in patients with thalassemia. Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major. The development of a safe and effective chelator has been the goal for many years. Aims and Objective: It was aimed to compare the effect of deferiprone, deferoxamine and combination of deferiprone and deferoxamine on serum ferritin value in betathalassemia patients. Material and Methods: This controlled clinical trial was conducted on 46 major beta-thalassemic patients. Fifteen patients in deferiprone group received deferiprone 75mg/kg/day three times a day orally. Nineteen patients in deferoxamine group received deferoxamine 30-50 mg/kg/day subcutaneously for 8-12 hours/day and 5 days per week. Twelve patients in combined therapy group received deferiprone 75 mg/kg/day three times a day orally with deferoxamine 30–50 mg/kg subcutaneously every other day. Serum ferritin value was th th measured at the beginning and at the end of 6 and 12 months of study. Results: The mean of serum ferritin value in deferiprone group insignificantly increased from 2731± 1398.5 µg/L at the beginning to 2788.5 ± th 978.6 µg/L and to 3331.8 ± 1833.9 µg/L at the end of 6 th and 12 months of study, respectively. The mean of serum ferritin value in deferoxamine group insignificantly increased from 2883.5 ± 1598.1 µg/L at the th beginning to 2935.3 ± 1258.2 µg/L at the end of 6 month of study and decreased to 2773.8 ± 1216.1 µg/L th and 12 month of study. The mean of serum ferritin level in combined therapy group significantly decreased from 7498.7 ± 3512.9 µg/L at the beginning to 4839.9 ± 2698.2 µg/L (P < 0.001) and to 4298.2 ± th th 2288.7 µg/L (P < 0.001) at the end of 6 and 12 months of study, respectively. Conclusion: Combined therapy significantly decreases serum ferritin level. Study suggests deferiprone as a significant addition to support therapy in patients with betathalassemia major on regular transfusion regimens.http://jkimsu.com/jkimsu-vol4no1/JKIMSU,%20Vol.%204,%20No.%201,%20Jan-Mar%202015%20Page%2070-76.pdfDeferiproneDeferoxamineFerritinBeta-thalassemia |
| spellingShingle | Nargesbeygom Mirbehbahani Azam Jahazi Haniye Mohsenkhah Amlashi Naser Behnampour Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients Journal of Krishna Institute of Medical Sciences University Deferiprone Deferoxamine Ferritin Beta-thalassemia |
| title | Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients |
| title_full | Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients |
| title_fullStr | Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients |
| title_full_unstemmed | Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients |
| title_short | Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients |
| title_sort | comparative efficacy of deferiprone deferoxamine and combination of deferiprone and deferoxamine on serum ferritin value in beta thalassemia patients |
| topic | Deferiprone Deferoxamine Ferritin Beta-thalassemia |
| url | http://jkimsu.com/jkimsu-vol4no1/JKIMSU,%20Vol.%204,%20No.%201,%20Jan-Mar%202015%20Page%2070-76.pdf |
| work_keys_str_mv | AT nargesbeygommirbehbahani comparativeefficacyofdeferipronedeferoxamineandcombinationofdeferiproneanddeferoxamineonserumferritinvalueinbetathalassemiapatients AT azamjahazi comparativeefficacyofdeferipronedeferoxamineandcombinationofdeferiproneanddeferoxamineonserumferritinvalueinbetathalassemiapatients AT haniyemohsenkhahamlashi comparativeefficacyofdeferipronedeferoxamineandcombinationofdeferiproneanddeferoxamineonserumferritinvalueinbetathalassemiapatients AT naserbehnampour comparativeefficacyofdeferipronedeferoxamineandcombinationofdeferiproneanddeferoxamineonserumferritinvalueinbetathalassemiapatients |